Explore our media
Learn more about ACTO and the life sciences industry at large through ACTO’s podcast, blogs, events, and more
Featured blogs
Episode 6 | Alison Muller
Compliant AI for Pharma & Med Device: Holding Agents to Human Standards
February 27, 2026
Picture this: you’re a new medical science liaison (MSL) at a top pharma company. It’s Day 1. You walk into the Head of Medical Affairs’ office and say, “I’d like to start customer meetings on Monday.“ You’d be laughed out of the building. And rightly so—because in this highly-regulated industry, no human representing a pharmaceutical, biotech, or medical device company
Episode 6 | Alison Muller
The First Six Months of a Biopharma Launch: Why Early Execution Determines Long-Term Performance
February 26, 2026
In emerging biopharma, approval isn’t the finish line.It’s the starting gun. The first six months of a biopharma launch don’t just influence performance—they lock it in. Industry data consistently show that most long-term commercial outcomes are effectively set before teams have time to “optimize later.” For companies launching their first product, this isn’t simply a pharmaceutical launch milestone. It’s a
Pulse is your ultimate source of relevant and innovative strategy
Subscribe today to stay up to date in all thing industry
Subscribe
Recent Articles
Episode 6 | Alison Muller
Compliant AI for Pharma & Med Device: Holding Agents to Human Standards
February 27, 2026
Picture this: you’re a new medical science liaison (MSL) at a top pharma company. It’s Day 1. You walk into the Head of Medical Affairs’ office and say, “I’d like to start customer meetings on Monday.“ You’d be laughed out of the building. And rightly so—because in this highly-regulated industry, no human representing a pharmaceutical, biotech, or medical device company
Episode 6 | Alison Muller
The First Six Months of a Biopharma Launch: Why Early Execution Determines Long-Term Performance
February 26, 2026
In emerging biopharma, approval isn’t the finish line.It’s the starting gun. The first six months of a biopharma launch don’t just influence performance—they lock it in. Industry data consistently show that most long-term commercial outcomes are effectively set before teams have time to “optimize later.” For companies launching their first product, this isn’t simply a pharmaceutical launch milestone. It’s a